Krsnaa Diagnostics board has approved the sale of diagnostic equipment worth up to ₹120 crore, a move aimed at improving asset management and capital efficiency.

Board decision on equipment sale

The board of Krsnaa Diagnostics greenlit the disposal of identified diagnostic equipment, with the total transaction value capped at ₹120 crore. The decision reflects the company's focus on optimising its asset base through the structured sale of assets to identified purchasers, including those that may be identified in the future.

Strategic rationale

The board-sanctioned sale is directed at improving asset management within the organisation. By divesting diagnostic equipment up to the approved value, Krsnaa Diagnostics aims to streamline its operational asset portfolio. The proposed transaction forms part of the company’s ongoing strategic initiative to transition towards an increasingly asset-light and capital-efficient operating model.

The company stated that it has identified certain assets that can be monetised without impacting its core operating capabilities. The sale is intended to unlock value from these assets and facilitate efficient recycling of capital towards the core diagnostic business and identified growth opportunities. This initiative is expected to support improved asset utilisation, enhance return on capital employed (ROCE), and strengthen the balance sheet.

Asset details and regulatory compliance

The assets proposed for sale comprise identified freehold assets which are not subject to any security interest created in favour of the company’s lenders. Accordingly, the transaction will not impact the assets forming part of the security package provided to lenders. The board clarified that this exercise is one of active portfolio and capital optimisation and is not driven by any impairment or diminution in the value of the underlying assets.

The transaction does not constitute a sale or disposal of an undertaking within the meaning of Section 180(1)(a) of the Companies Act, 2013. The board authorised the Operations Committee to finalise the terms and conditions of the transaction within the aggregate limit approved.

Krsnaa Diagnostics Limited held its 16th Annual General Meeting (AGM) on Monday, September 28, 2026, at its registered office in Pune, Maharashtra. The meeting commenced at 11:00 am and concluded at 12:10 pm, attended by 36 members either in person or through authorised representatives.

The proceedings were chaired by Rajendra Mutha, Chairperson and Whole Time Director, who confirmed the requisite quorum. Sujoy Sudipta Bose, Company Secretary and Compliance Officer, welcomed the attendees and introduced the directors and key executives present on the dais.

Leadership and key personnel attendance

Seven directors were present in person at the venue, including the Managing Director and several independent directors overseeing critical committees such as Audit and Stakeholders Relationship. Key Managerial Personnel (KMPs) also attended the meeting.

Key managerial personnel present

The following Key Managerial Personnel attended the meeting in person:

• Mitesh Dave: Group Chief Executive Officer
• Chandra Prakash Singh: Interim Chief Financial Officer
• Sujoy Bose: Company Secretary and Compliance Officer

Auditor and scrutinizer representation

Representatives from the statutory auditor, secretarial auditor, and cost auditor firms were present to oversee the procedural aspects of the AGM.

The company filed the summary of proceedings with stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.